Be Biopharma Announces $82M Financing to Advance Gene Therapy

Gunderson Dettmer represented client Be Biopharma, a leader in the discovery and development of engineered B Cell Medicines (BCMs), in its $82 million financing. The financing had big pharma involvement in the form of Bristol Myers Squibb and Takeda Ventures, with venture capital firms ARCH Venture Partners, Atlas Venture, and RA Capital Management participating. Be Bio is pioneering Engineered BCMs to dramatically improve the lives of patients who are living with Hemophilia B and other genetic diseases, cancer, and other serious conditions. The new capital will be used for Be Bio’s hemophilia B candidate BE-101 and a newly unveiled program for hypophosphatasia called BE-102.

In the announcement of the transaction, Be Bio Chief Executive Officer Joanne Smith-Farrell, Ph.D. said, "Advancing two BCMs that harness the potential of this new modality represents an exciting step in transforming the treatment landscape for their respective indications with potentially best-in-class genetic medicines. With support from a top-tier syndicate of investors and pharmaceutical companies, we are eager to clinically demonstrate BE-101’s potential to provide a highly durable FIX replacement therapy for Hemophilia B patients. Additionally, we are excited to advance BE-102 to address the needs of a large patient population with few to no therapeutic options.”

The Gunderson Dettmer deal team was led by Tim Ehrlich and included Gregory Kinzelman, Timothy Kulis, Joel Diamond and Morgan Clarke.

Company
Be Biopharma